
Unmet Needs
Understanding crucial unmet needs and identifying opportunities in drug development with a focus on specific indications and insights into how well current or emerging therapies are poised to meet them.
Formerly known as BioTrends, we use our deep therapeutic expertise, layered onto data-driven insights, to support product success throughout the entire commercialization cycle. We provide our customers with brand trends & insights by using brand-centric market research. This research allows us to address not only the performance of brands and competitors in the marketplace, but also treatment decision drivers, including physician perception, awareness, and uptake.
Our innovative insights uncover the why, what, and how of brand performance
Understanding crucial unmet needs and identifying opportunities in drug development with a focus on specific indications and insights into how well current or emerging therapies are poised to meet them.
Our solutions combine resolution physician network analysis with quantifiable payer and health system influence to identify the most influential physicians and institutions that are likely to have the highest impact on a community of practice.
Our blend of clinical development experience, internal market planning tools, and therapeutic expertise uniquely positions our team to support the product development process.
In this project, commissioned by Incyte in February, 2021, we have packaged...
Treatment for recurrent or metastatic squamous cell carcinoma of the head and...
Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb /...
The schizophrenia therapy market is very crowded. Many of the antipsychotic...
The wet age-related macular degeneration (AMD) therapy market has long been...
Digital pharmacies, which provide a faster and easier way to get prescriptions, are implementing new technologies to improve...
In DRG Blog / Feb, 2021
In the United States, as the COVID-19 pandemic shuttered non-essential businesses, millions lost their jobs and with them...
In DRG Blog / Feb, 2021
The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 marked...
In DRG Blog / Feb, 2021
From potential shortages of generic drugs to a brand new COVID-19 pipeline, this pandemic is undoubtedly impacting pharmacy...
In DRG Blog / Feb, 2021
While big PBMs like ESI and CVS Caremark promote exceptional market control through their 2019 PBM trend reports, Prime...
In DRG Blog / Jan, 2021
In the news
News articles citing DRG analysts data.